The second clear takeaway was the coming nuclear winter in late-stage tech/growth investing. Late stage defined as the final private round before the company goes for an initial public offering (IPO). Crossover funds/ hedge funds are in intense pain and they were the major players in the late-stage game. Many of these funds had invested 20-25 per cent of their assets in late stage privates. The public book is down 50 per cent, thus taking the private weight to 40 per cent. These funds are now facing redemptions and thus will have to further sell down their public book, taking the private stock weight up even further. Suddenly, many of these funds will have a majority of their assets in private stock. This is not their mandate. The private exposure will have to be reduced. Expect to see a wave of secondary transactions and very limited appetite for incremental private investments from these funds. Late stage is where the pain will be maximum. A correction here will obviously pressurise the IPO markets. Only the best tech start-ups will be able go for an IPO and that too at much lower prices than currently envisaged. Many others will be stuck, neither able to raise money via IPO nor access new rounds at their last valuation. We are going to see down rounds. This will be messy, as down rounds bring into focus the tussle between funds not wanting to mark down and companies needing the money. Preferred return structures will also come into focus. Late stage companies will have to pivot towards profitability, the reality is that all business models will not be able to make this transition. Many founders have never had to worry about profits or cash flows, only growth. That environment is gone. Early stage venture capital funding has more dedicated capital and there is a lot of investor appetite even today. Here we will see a correction in valuations, but funding will happen, there will not be a lack of investment capital as is likely in the late-stage rounds.